Any cardiovascular protection from colchicine in heart attack survivors seemed to be debunked with a better-powered randomized trial, researchers found. Between acute MI patients randomized to ...

WASHINGTON — Colchicine does not protect against major cardiovascular adverse events after an acute myocardial infarction, according to a multinational placebo-controlled trial of more than 7000 ...

Colchicine does not significantly reduce perioperative atrial fibrillation (AF) or myocardial injury after non-cardiac surgery (MINS) in patients undergoing major non-cardiac thoracic surgery, ...

NEW YORK — New insights into colchicine's disruption of the pathway that contributes to arterial inflammation and new clinical studies of the drug could pave the way toward greater use of the ...

AMSTERDAM -- Anti-inflammatory colchicine (Lodoco) given perioperatively around major non-cardiac thoracic surgery did not cut atrial fibrillation (Afib) or myocardial injury complications, the COP-AF ...

Please provide your email address to receive an email when new articles are posted on . Historical use of colchicine, or its precursors, dates back several thousand years, with reports appearing in ...

Please provide your email address to receive an email when new articles are posted on . Patients taking colchicine had a weighted hazard ratio of 0.82 (95% CI, 0.69-0.94) for cardiovascular events.

Colchicine is one of the oldest medicines with potent anti-inflammatory functions, widely used to treat rheumatic diseases such as gout, calcium pyrophosphate deposition disease (CPDD), and familial ...

PHILADELPHIA, PA—Colchicine, given orally prior to PCI in an all-comers population, does not reduce procedure-related myocardial injury, but does appear to attenuate the inflammatory response, results ...